Wednesday, September 29, 2010 (Last Updated: 09/29/2010)
WEDNESDAY, Sept. 29 (HealthDay News) -- Insulin-like growth factor receptor 1 (IGF-1R) may present a therapeutic target in women with triple-negative breast carcinoma, according to research presented at the American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development, held from Sept. 27 to 30 in Denver.
Jessica Kline, of Thomas Jefferson University in Philadelphia, and colleagues analyzed data from 97 triple-negative breast carcinoma samples. They scored IGF-1R protein expression using standardized criteria and categorized the scores as low or high.
The researchers found a significant association between IGF-1R protein expression and IGF-1R gene amplification. Low expression of IGF-1R was associated with lymph node metastases, and high expression was associated with smaller tumor size at a borderline statistical significance (P = 0.08). A high IGF-1R score in patients under 55 was associated with longer survival.
Blocking IGF-1R has been helpful in sarcomas, according to one of the researchers in a prepared statement, who added that, "for now, we know that it is there and we know it is a marker of better prognosis. The next step is to learn if triple-negative breast cancer patients benefit from targeting IGF-1R."
A co-author is employed by Ventana Medical Systems Inc.
Hematology & Oncology
OBGYN & Women's Health
Copyright © 2010 HealthDay. All rights reserved.